Compared with the non-MetS group, subjects in the newly-MetS group had significantly higher BMI, WC, SBP, DBP, TG, TC, LDL-C, FPG, HbA1c, Fasting insulin, HOMA-IR, γ-GGT, and lower HDL-C, TT, LH and SHBG at baseline (all p<0.05). The gene discussed is INS; the disease is metabolic syndrome.